PBPK MODELING OF SHORT-TERM (0 TO 5 MIN) HUMAN INHALATION EXPOSURES TO HALOGENATED HYDROCARBONS

Allowable human exposure to Halons and Halon replacement chemicals is often regulated on the basis of cardiac sensitization potential. Exposure guidelines are established using dose-response data obtained from animal testing. Results from animal tests are often summarized by no-observable-adverse-effect level and lowest-observable-adverseeffect level values. This threshold approach alone does not provide the information necessary to evaluate the cardiac sensitization potential for the chemical of interest under a variety of exposure concentrations and durations. In order to provide a tool for decision makers and regulators tasked with setting exposure guidelines for Halon replacement chem icals, a quantitative approach was established that allows exposures to be assessed in terms of the chemical concentrations in blood during the exposure. A physiologically based pharmacokinetic model was modified to include a respiratory-tract compartment containing a dead-space region and a pulmonary exchange area. The ...

[1]  E K Fram,et al.  Morphometric characteristics of cells in the alveolar region of mammalian lungs. , 2015, The American review of respiratory disease.

[2]  G. W. Jepson,et al.  Cardiac sensitization thresholds of halon replacement chemicals predicted in humans by physiologically-based pharmacokinetic modeling. , 1996, Risk analysis : an official publication of the Society for Risk Analysis.

[3]  J. Fisher,et al.  Rat to human extrapolation of HCFC-123 kinetics deduced from halothane kinetics: a corollary approach to physiologically based pharmacokinetic modeling. , 1996, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[4]  J W Fisher,et al.  Dose-dependent metabolism of 2,2-dichloro-1,1,1-trifluoroethane: a physiologically based pharmacokinetic model in the male Fischer 344 rat. , 1994, Toxicology and applied pharmacology.

[5]  R Rubenstein,et al.  Mechanistic insights aid the search for CFC substitutes: risk assessment of HCFC-123 as an example. , 1994, Risk analysis : an official publication of the Society for Risk Analysis.

[6]  R. Dirksen,et al.  A system model for closed-circuit inhalation anesthesia. I. Computer study. , 1991, Anesthesiology.

[7]  R. Dirksen,et al.  A system model for closed-circuit inhalation anesthesia. II. Clinical validation. , 1991, Anesthesiology.

[8]  R. Weiskopf,et al.  Kinetics of desflurane, isoflurane, and halothane in humans. , 1991, Anesthesiology.

[9]  S. Almog,et al.  Fatal Accidental Inhalation of Bromochlorodifluoromethane (Halon 1211) , 1991, Human & experimental toxicology.

[10]  D. Holaday Absorption, biotransformation, and storage of halothane , 1977, Environmental health perspectives.

[11]  D. Holaday,et al.  Resistance of Isoflurane to Biotransformation in Man , 1975, Anesthesiology.

[12]  A. J. Bailer,et al.  The impact of exercise and intersubject variability on dose estimates for dichloromethane derived from a physiologically based pharmacokinetic model. , 1994, Fundamental and applied toxicology : official journal of the Society of Toxicology.